SETD2 and cutaneous melanoma: In order to further verify the biomarker value of SETD2 mutation in immunotherapy in cutaneous melanoma, we analyzed the data from Memorial Sloan Kettering Cancer Center (MSKCC), in which samples had undergone immunotherapy.